Vasopharm Gets $7M to Prep for Pivotal Brain Injury Trial

Vasopharm GmbH raised €5 million (US$6.5 million) in new investment to fund preparations for a Phase III trial of VAS203, an allosteric inhibitor of nitric oxide (NO) synthase in development for treating traumatic brain injury (TBI).